Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disea source ↗
Raise Follow-on offering: $130M (total, as published), announced Jan 7, 2026. Source: SEC filing. source ↗
Trial start Phase 2: A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks source ↗
Trial start —: A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring source ↗
Trial start Phase 1: A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in source ↗
Trial start Phase 1: A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily source ↗
Trial start Phase 1: A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease source ↗
Trial start Phase 1: A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants source ↗
Trial start Phase 1: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease source ↗
Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) source ↗
Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease source ↗
Trial start Phase 1: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants source ↗
Trial start Phase 1: Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants source ↗
Trial start Phase 1: Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants source ↗
Trial start Phase 3: Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection source ↗
Trial start Phase 3: Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis source ↗
Upcoming milestones
2026-10 (ESTIMATED) · Phase 2 · A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks · NCT06851559
Oct 20, 2027 (ESTIMATED) · Phase 3 · A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Throug · NCT07752407
2034-09 (ESTIMATED) · · A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring · NCT06660342
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $130.0M. Last 2 years.
Follow-on offering: $130M (total, as published), announced Jan 7, 2026. Source: SEC filing. source ↗
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
